2 unloved penny stocks I’m considering buying today!

These penny stocks may have fallen out of favour with UK investors, but I think they could be too cheap to miss following share price falls.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Man smiling and working on laptop

Image source: Getty images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m searching for great penny stocks to buy following heavy share price weakness. Here are two I think are highly attractive at current prices.

Medical marvel

Medical technology business Polarean Imaging (LSE:POLX) has passed some significant milestones in recent months.

Its landmark XENOVIEW product — which allows MRI scans to give a more complete picture of a patient’s lung health — was signed off by the US Food and Drug Administration (FDA) at the end of 2022. Then in May, the first clinical scan took place at an Ohio hospital using the technology. This followed the company’s maiden sale a month earlier.

So what’s gone wrong with the Polarean share price? As is often the case with penny stocks, it’s money.

The business had a healthy $16m of cash on its balance sheet at the end of last year. But in February, it announced that “the company will need additional cash resources to achieve the 24 month commercial targets and to pursue the development of the next indications and their approvals, and advanced R&D for future products.

A dip-buying opportunity

Chart showing forecast growth in the chronic obstructive pulmonary disease (COPD) treatment market Forecast (In US Dollars)
Predicted growth in the global chronic obstructive pulmonary disease (COPD) treatment market (in US dollars). Source: Precedence Research

Tapping shareholders for cash is one option the business is exploring to plug the funding gap. Yet given recent share price weakness, I’m still considering adding some Polarean shares to my portfolio.

City analysts expect Polarean’s sales to more than double from around $3m this year to $8m in 2024. This is possibly no surprise given the advantages its technologies provide for both medical personnel and patients.

The company’s technology not only provides clearer images, but they can be taken without the use of harmful radiation and don’t require invasive procedures. As the number of people suffering lung-related problems explodes, XENOVIEW has huge growth potential.

The number of people seeking treatment for chronic obstructive pulmonary disease (COPD) alone is tipped to soar over the next decade, as the graph above shows. Soaring cases of asthma, cancer and other conditions also mean demand for Polarean’s expertise could grow strongly.

A top dividend stock

Making a second income from penny stocks can be a difficult task. Usually, any surplus cash these growth-oriented shares make is ploughed back into the business rather than paid out in dividends.

Property stock Alternative Income REIT (LSE:AIRE) is one small-cap share that could provide a passive income however. Under real estate investment rules its required to distribute at least 90% of annual rental profits out by way of dividends.

This is why the firm offers up a huge 8.2% forward dividend yield. That’s more than double a corresponding 3.8% reading for FTSE 100 shares.

Alternative Income invests in a diverse range of real estate assets. This means that, while it can still theoretically struggle to collect rents during downturns, the risk is much reduced. The firm’s portfolio includes hotels, gyms, logistics hubs and care homes.

Encouragingly, 96% of the rental income it receives is inflation linked. This makes it an especially attractive penny stock to own in this period of rampant price rises.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Number three written on white chat bubble on blue background
Investing For Beginners

3 investing mistakes to avoid when buying UK shares for 2025

Jon Smith flags up several points for investors to note when it comes to thinking about which UK shares to…

Read more »

Investing Articles

Will the rocketing Scottish Mortgage share price crash back to earth in 2025?

The recent surge in the Scottish Mortgage share price caught Harvey Jones by surprise. He was on the brink of…

Read more »

Investing Articles

2 cheap shares I’ll consider buying for my ISA in 2025

Harvey Jones will be on the hunt for cheap shares for his ISA in 2025 and these two unsung FTSE…

Read more »

Investing Articles

I am backing the Glencore share price — at a 3-year low — to bounce back in 2025

The Glencore share price has been falling for some time, but Andrew Mackie argues demand for metals will reverse that…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

A 10% dividend yield? There could be significant potential here to earn a second income

Mark Hartley delves into the finances and performance of one of the top-earning dividend stocks in his second income portfolio.

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Charlie Munger recommended shares in this growth company back in 2022. Here’s what’s happened since

One of Charlie Munger’s key insights is that a high P/E ratio shouldn’t put investors off buying shares if the…

Read more »

Investing Articles

What might 2025 have in store for the Aviva share price? Let’s ask the experts

After a rocky five years, the Aviva share price has inched up in 2024. And City forecasters reckon we could…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Trading around an 11-year high, is Tesco’s share price still significantly undervalued?

Although Tesco’s share price has risen a lot in the past few years, it could still have significant value left…

Read more »